131 related articles for article (PubMed ID: 11786592)
1. Multinomial phase II trial designs.
Freidlin B; Dancey J; Korn EL; Zee B; Eisenhauer E
J Clin Oncol; 2002 Jan; 20(2):599. PubMed ID: 11786592
[No Abstract] [Full Text] [Related]
2. Newer phase II trial designs gaining ground.
Benowitz S
J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
[No Abstract] [Full Text] [Related]
3. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
[No Abstract] [Full Text] [Related]
4. Criticism of tumor response criteria raises trial design questions.
Twombly R
J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
[No Abstract] [Full Text] [Related]
5. Phase II clinical trials in oncology: are we hitting the target?
Ang MK; Tan SB; Lim WT
Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
[TBL] [Abstract][Full Text] [Related]
6. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
7. Is response rate relevant to the phase II trial design of targeted agents?
Dowlati A; Fu P
J Clin Oncol; 2008 Mar; 26(8):1204-5. PubMed ID: 18285601
[No Abstract] [Full Text] [Related]
8. Optimal two-stage randomized multinomial designs for Phase II oncology trials.
Sun LZ; Chen C; Patel K
J Biopharm Stat; 2009; 19(3):485-93. PubMed ID: 19384690
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
10. Examining heterogeneity in phase II trial designs may improve success in phase III.
Tuma RS
J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
[No Abstract] [Full Text] [Related]
11. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
12. Optimizing randomized phase II trials assessing tumor progression.
Stone A; Wheeler C; Carroll K; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
[TBL] [Abstract][Full Text] [Related]
13. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
14. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH; Eisenhauer EA
J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
[TBL] [Abstract][Full Text] [Related]
15. A two-stage phase II trial design utilizing both primary and secondary endpoints.
Lin X; Allred R; Andrews G
Pharm Stat; 2008; 7(2):88-92. PubMed ID: 17252536
[TBL] [Abstract][Full Text] [Related]
16. Design of phase II ALS clinical trials.
Schoenfeld DA; Cudkowicz M
Amyotroph Lateral Scler; 2008; 9(1):16-23. PubMed ID: 18273715
[TBL] [Abstract][Full Text] [Related]
17. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
Ratain MJ; Eckhardt SG
J Clin Oncol; 2004 Nov; 22(22):4442-5. PubMed ID: 15483011
[No Abstract] [Full Text] [Related]
18. Developing drugs that do not cause tumor regression.
Stadler W
Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462
[No Abstract] [Full Text] [Related]
19. Clinical trial designs for multiple myeloma.
Hoering A; Crowley J
Clin Adv Hematol Oncol; 2007 Apr; 5(4):309-16. PubMed ID: 17607290
[TBL] [Abstract][Full Text] [Related]
20. Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.
Francart J; Legrand C; Sylvester R; Van Glabbeke M; van Meerbeeck JP; Robert A
J Clin Oncol; 2006 Jul; 24(19):3007-12. PubMed ID: 16809726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]